Quarterly Device Clearance Digest — Q2 2026

This quarter brought a wave of aesthetic device approvals. Laser systems dominated: LumiGlam Laser System (Beijing Sano), LASEmaR 1500 (Eufoton), and MILAN System (Lumenis Be) all cleared for general and plastic surgery use. Radiofrequency platforms—Veineo System (F Care Systems USA) and VIVA combo RF System (Starmed)—address skin tightening and body contouring. Sanhe LEFIS's Intense Pulsed Light device and CurrentBody's LED Multi Light Therapy Mask round out the mix. All received substantially equivalent determinations, meaning they cleared predicate pathways rather than novel mechanisms. For buyers, this signals regulatory confidence but not necessarily clinical differentiation from existing platforms.

Substantial equivalence is a regulatory green light, not a clinical guarantee. The LumiGlam, LASEmaR 1500, and MILAN systems join an already crowded laser market. Before committing capital, practices should request head-to-head efficacy data, downtime profiles, and real-world treatment costs versus established competitors. LED and IPL devices, too, are entering a mature category. The CurrentBody mask and Sanhe IPL device may offer price or ergonomic advantages, but verify clinical outcomes and patient satisfaction in your target demographic. Predicate clearance is fast; clinical validation takes time.

Radiofrequency remains a high-margin category, and two new RF platforms cleared this quarter. Veineo System and VIVA combo RF System both target skin tightening and body contouring. Practices already running RF devices (Thermage, Exilis, others) should evaluate whether new entrants offer meaningful advantages: faster treatment times, lower cost per handpiece, better patient comfort, or superior results. The RF market is competitive but not saturated; there is room for differentiation. Request clinical data, training requirements, and long-term service/parts availability before purchasing.

Bausch Health filed three material-event 8-Ks (March, April, May 2026) involving Solta, its aesthetic division. Solta owns Thermage, Fraxel, and Clear+Brilliant—cornerstone devices for many practices. Material events often precede spin-offs, divestitures, or M&A. For practice owners, this creates uncertainty: Will Solta remain independent? Will new ownership change pricing, support, or warranty terms? Will training and parts availability shift? Practices heavily invested in Solta equipment should monitor SEC filings closely, budget for potential price increases, and consider diversifying into non-Solta platforms. Contact your Solta rep directly for clarity on corporate direction.

Bausch Health's Phase 4 skin-resurfacing trial remains active but not recruiting, suggesting enrollment is complete or paused. Erchonia's laser skin-laxity trial was terminated early—a red flag for efficacy or recruitment challenges. Neither trial directly affects current practice decisions, but the Erchonia termination signals caution around that vendor's newer aesthetic claims. Practices considering Erchonia devices should request published efficacy data and ask why the trial ended prematurely.

Before purchasing any newly cleared device: (1) Request clinical data beyond FDA predicate equivalence; (2) Compare cost per treatment and patient outcomes to established competitors; (3) Verify training, support, and parts availability; (4) For Solta equipment, clarify corporate stability with your rep; (5) Assess downtime and patient satisfaction in your specific patient population; (6) Negotiate service agreements and warranty terms. Substantial equivalence is a floor, not a ceiling. Due diligence remains essential.